Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 67 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Follow-Up Questions
Abivax SA (AAVXF) 的本益比是多少？
Abivax SA 的本益比是 N/A
Abivax SA 的 CEO 是誰？
Mr. Marc De Garidel 是 Abivax SA 的 Chief Executive Officer，自 2023 加入公司。
